FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
· theguardian.com · popularity 27/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at theguardian.com →
Summary
The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – which can facilitate weight loss – over a rare eye condition that could lead to sudden and permanent blindness . On Monday, the FDA announced that it is requiring all GLP-1 medications – including Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound, as well as Sanofi’s Soliqua – to include information about the potential risk of nonarteritic anterior ischemic optic neuropathy, also known as NAION, on warning labels. Continue reading...
Found in: Guardian World. Rating basis: single outlet; outlet tier 5; 1 feeds; feed position 43.